Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.
Acta Derm Venereol. 2022 Jan 18;102:adv00631. doi: 10.2340/actadv.v101.910.
Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9-14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.
在一项中位随访时间为 1 年的芬兰重度斑块状银屑病真实世界队列中，评估了古塞单抗的治疗结局和持续性。从 15 个研究中心的患者病历中回顾性地收集了 181 名开始使用古塞单抗的患者的数据。先前暴露于生物制剂治疗很常见，分别有 56%和 35%的患者至少使用过 1 种和 2 种生物制剂。古塞单抗的中位治疗持续时间为 11 个月，21 名（12%）患者在随访期间停止治疗。在至少随访 1 年的 85 名患者中，73 名（86%）患者在 1 年内仍继续使用古塞单抗。在随访期间，绝对银屑病面积和严重程度指数（PASI）评分显著改善，32 名（80%）患者在治疗 9-14 个月后绝对 PASI ≤ 2。古塞单抗治疗在芬兰全国真实环境中有效，治疗持续时间长。
